PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32828280-0	2020	Rosiglitazone binds to RXRalpha to induce RXRalpha tetramerization and NB4 cell differentiation.	Rosiglitazone	0-13	retinoid X receptor alpha	Homo sapiens	23-31	
32828280-0	2020	Rosiglitazone binds to RXRalpha to induce RXRalpha tetramerization and NB4 cell differentiation.	Rosiglitazone	0-13	retinoid X receptor alpha	Homo sapiens	42-50	
32828280-1	2020	Rosiglitazone is a ligand of peroxisome proliferation-activated receptor gamma (PPARgamma).	Rosiglitazone	0-13	peroxisome proliferator activated receptor gamma	Homo sapiens	29-78	
32828280-1	2020	Rosiglitazone is a ligand of peroxisome proliferation-activated receptor gamma (PPARgamma).	Rosiglitazone	0-13	peroxisome proliferator activated receptor gamma	Homo sapiens	80-89	
32828280-3	2020	In this study, we defined that rosiglitazone was also a ligand of retinoid X receptor alpha (RXRalpha) and displayed RXRalpha-dependent activities.	Rosiglitazone	31-44	retinoid X receptor alpha	Homo sapiens	66-91	
32828280-3	2020	In this study, we defined that rosiglitazone was also a ligand of retinoid X receptor alpha (RXRalpha) and displayed RXRalpha-dependent activities.	Rosiglitazone	31-44	retinoid X receptor alpha	Homo sapiens	93-101	
32828280-3	2020	In this study, we defined that rosiglitazone was also a ligand of retinoid X receptor alpha (RXRalpha) and displayed RXRalpha-dependent activities.	Rosiglitazone	31-44	retinoid X receptor alpha	Homo sapiens	117-125	
32828280-4	2020	We found that rosiglitazone directly bound to the ligand binding domain (LBD) of RXRalpha and induced RXRalpha/LBD tetramerization.	Rosiglitazone	14-27	retinoid X receptor alpha	Homo sapiens	81-89	
32828280-4	2020	We found that rosiglitazone directly bound to the ligand binding domain (LBD) of RXRalpha and induced RXRalpha/LBD tetramerization.	Rosiglitazone	14-27	retinoid X receptor alpha	Homo sapiens	102-110	
32828280-5	2020	Rosiglitazone inhibited the agonist-induced transcriptional activity of RXRalpha homodimers and heterodimers likely through inhibiting RXRalpha homo- and hetero-dimerization.	Rosiglitazone	0-13	retinoid X receptor alpha	Homo sapiens	72-80	
32828280-5	2020	Rosiglitazone inhibited the agonist-induced transcriptional activity of RXRalpha homodimers and heterodimers likely through inhibiting RXRalpha homo- and hetero-dimerization.	Rosiglitazone	0-13	retinoid X receptor alpha	Homo sapiens	135-143	
32828280-6	2020	In acute promyelocytic leukemia (APL) NB4 cells, rosiglitazone inhibited cell proliferation and induced cell differentiation, resulting from inhibiting RXRalpha/PML-RARalpha complex formation and down-regulating PML-RARalpha.	Rosiglitazone	49-62	retinoid X receptor alpha	Homo sapiens	152-160	
32828280-7	2020	Together, our study identified RXRalpha as a novel target of rosiglitazone and RXRalpha mediating the anti-APL activity of rosiglitazone.	Rosiglitazone	61-74	retinoid X receptor alpha	Homo sapiens	31-39	
32828280-7	2020	Together, our study identified RXRalpha as a novel target of rosiglitazone and RXRalpha mediating the anti-APL activity of rosiglitazone.	Rosiglitazone	123-136	retinoid X receptor alpha	Homo sapiens	31-39	
32828280-7	2020	Together, our study identified RXRalpha as a novel target of rosiglitazone and RXRalpha mediating the anti-APL activity of rosiglitazone.	Rosiglitazone	123-136	retinoid X receptor alpha	Homo sapiens	79-87